"Investors Helping Entrepreneurs"
Investment Stage: Seed
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 17.02.2026 | GelMEDIX, ... | gelmedix.com | $13M | United Sta... |
Mentions in press and media 6
| Date | Title | Description |
| 23.02.2026 | GelMEDIX Secures $13 Million to Advance Vision Restoration | GelMEDIX, a biotechnology innovator, closed a $13 million seed funding round. Safar Partners spearheaded the investment. This capital fuels the company's lead program, GMX-101. GMX-101 targets late-stage Geographic Atrophy, a devastating fo... |
| 17.02.2026 | GelMEDIX Raises $13M in Seed Funding | GelMEDIX, a Cambridge, MA-based biotechnology company developing regenerative therapies to restore vision, raised $13M in Seed funding. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Bosto... |
| 17.02.2026 | GelMEDIX: $13 Million Seed Funding Closed For Vision Restoration Biotechnology Platform | GelMEDIX, a biotechnology company developing regenerative therapies to restore vision, has completed a $13 million seed financing round led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Bost... |
| 18.12.2012 | Golden Seeds joins $6.4M financing round for therapeutic combating ulcerative colitis | Cherrystone Angel Group, an existing investor, co-led the round with Golden Seeds. Other investors participating in the round were Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, and North Country Angels; ... |
| 14.10.2008 | Harvard Spins Off Brand Monitoring Startup Crimson Hexagon | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Harvard’s Office of Technology Development has been grabbing headlines this week. On Sunday, it went public with news about a Beverly, MA-based spinoff called SiOnyx that hope... |
| - | Golden Seeds joins $6.4M financing round for therapeutic combating ulcerative colitis | A pharmaceutical startup gearing up for clinical trials for its antibody targeting digestive maladies has raised $6.4 million in a Series B financing round. Golden Seeds, an angel investment group that typically allocates funds to life scie... |